Anti-Daratumumab Antibodies
-
Bioanalytical Antibodies
-
Anti-idiotypic Antibodies
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Anti-idiotypic Antibodies
s
s
s
Antibodies for bioanalysis and drug monitoring of daratumumab and biosimilars
Develop highly selective and sensitive PK and ADA assays for daratumumab (Darzalex) using our range of ready-made antibodies.
- Recombinant antibodies specific to daratumumab
- Fully human format for surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Stringent quality control for batch to batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Daratumumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Daratumumab Inhibitory Type 1 |
HCA364 |
AbD45015ia |
Human IgG1 |
0.9 |
PK bridging ELISA capture and detection ADA control |
|
|
HCA365 |
AbD44788ia |
Human IgG1 |
3 |
ADA control |
||
|
HCA366 |
AbD44786ia |
Human IgG1 |
9 |
ADA control |
* Affinity measured in the monovalent Fab format.
Anti-Daratumumab Inhibitory Antibodies
Type 1 anti-daratumumab antibodies inhibit the binding of the monoclonal antibody drug daratumumab to its target, CD38. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. They are available in fully human IgG1 format, in three different affinities, for use as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Daratumumab PK bridging ELISA using antibody HCA364.
Schematic image of PK bridging ELISA. Anti-idiotypic capture and detection antibodies, Ig format (blue), monoclonal antibody drug (gold), detection antibody labeled with HRP.
ADA Bridging ELISA
Fig. 2. Daratumumab ADA bridging ELISA using antibody HCA364, HCA365, or HCA366.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Product
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.